May 22 |
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
|
May 8 |
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript
|
May 8 |
Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
|
May 8 |
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call
|
May 8 |
Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript
|
May 7 |
The 3 Best Nasdaq Stocks to Buy in May 2024
|
May 7 |
Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges
|
May 7 |
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
|
May 7 |
Rhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93M
|
May 7 |
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
|